KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Assets Average (2016 - 2025)

Jazz Pharmaceuticals has reported Assets Average over the past 15 years, most recently at $11.5 billion for Q4 2025.

  • Quarterly results put Assets Average at $11.5 billion for Q4 2025, down 5.16% from a year ago — trailing twelve months through Dec 2025 was $11.5 billion (down 5.16% YoY), and the annual figure for FY2025 was $11.8 billion, up 1.14%.
  • Assets Average for Q4 2025 was $11.5 billion at Jazz Pharmaceuticals, up from $11.2 billion in the prior quarter.
  • Over the last five years, Assets Average for JAZZ hit a ceiling of $12.8 billion in Q3 2021 and a floor of $6.6 billion in Q1 2021.
  • Median Assets Average over the past 5 years was $11.3 billion (2023), compared with a mean of $11.2 billion.
  • Biggest five-year swings in Assets Average: soared 107.88% in 2021 and later fell 15.98% in 2022.
  • Jazz Pharmaceuticals' Assets Average stood at $12.4 billion in 2021, then dropped by 14.36% to $10.6 billion in 2022, then rose by 6.49% to $11.3 billion in 2023, then rose by 7.39% to $12.1 billion in 2024, then decreased by 5.16% to $11.5 billion in 2025.
  • The last three reported values for Assets Average were $11.5 billion (Q4 2025), $11.2 billion (Q3 2025), and $11.2 billion (Q2 2025) per Business Quant data.